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DrRichard I.Whyte (Stanford, Calif).Dev, congratulations on
a nice presentation, and thank you for sending me the manuscript
in advance.
I have a couple of comments, and the questions I will put at the
end.
I think this study nicely complements the paper we heard this
morning about EBUS versus mediastinoscopy. Here, you used
these patients who were undergoing bronchoscopic FM place-
ment as your platform for this technique, and I think it should
be noted that the use of FMs is clearly decreasing. As the technol-
ogy of SBRT is getting better and better, the need for FMs is de-
creasing, and perhaps that will affect whether you do this, but I
suspect not.
The focus of this paper, obviously, is on PET and CT. In this
study, you used 5 mm as an indication for biopsy, and I was not re-
ally clear from the manuscript what you used as your criteria for
PET and CT, whether it was 10 mm or 5 mm in the short-axis di-
ameter or what the standard uptake value was. Interestingly, you
had flow cytometry as a criteria for being negative, and it would
be interesting to know whether that plays a significant role. But I
think, overall, you do indicate about a 15% false negative rate
for mediastinal node disease, and that is in keeping with the pub-
lished data. On a couple of your slides, however, I noticed that you
called the PET and CT findings false positives, and I think on 1
slide, you said that 9 of 11 had a false-positive rate on CT and 4
of 9 on PET. I think this assumes that your EBUS is actually truly
negative, and we do not really know that because we do not have
pathologic confirmation, and I suppose these false-positive PET
and CT findings could, in fact, be false-negative EBUS studies.
In general, I think that your conclusion that EBUS does upstage
and downstage some tumors in some patients is absolutely correct.
I think as to whether it is absolutely necessary, particularly in this
cohort of fairly sick patients, and whether that affects survival is
somewhat unclear. We do not have survival data, and often their
survival is more limited by their comorbidities.The Journal of Thoracic and CEssentially my questions are: What was the effect of flow cy-
tometry here? Was that really necessary, and did it affect which
findings were truly called negative? What were your criteria for
calling them abnormal on CT?Was it 5 mm, which I think is some-
what unconventional, or was it really 10 mm, which I think is
a more conventional number. Would you agree that some of these,
quote, ‘‘false positive’’ CT scans might, in fact, be false-negative
EBUS tests?
Overall, I enjoyed the paper. Thank you.
Dr Krimsky. Thank you very much.
The issuewith respect to the CT scans, I think, to be clear, it was
when the radiologist interpreting the CT scans called them
enlarged, and it was typically using a short-axis diameter of
10 mm or 1 cm. I do not think the flow cytometry helped very
much, for what that is worth.
Dr Shrager. What was the third question, Richard?
Dr Whyte. Some of these, quote ‘‘false-positive’’ and ‘‘false-
negative’’ CT and PET scans, could they really be false-negative
EBUS tests?
Dr Krimsky. Certainly. We have another study we are in the
process of finishing the data collection for to study the mediastinal
results and EBUS results at our particular institution, because data,
much like politics, is all local, and at least from the data we have so
far, the correlation rate is nearly perfect. Thus, I think the answer is
yes and yes, if that helps.
Dr Mark J. Krasna (Towson, Md). I will just follow-up with
that. That was a good presentation.
Bill, I guess I will put the question back to you as a comment. I
think your group has done a great job, especially since the Society
for Thoracic Surgery meeting, incorporating mediastinal nodal
staging. Similar to Dr Whyte, we are using FM-less systems;
thus, we do not need to perform bronchoscopy for that reason;
however, as you have trained us, we are using EBUS and mediasti-
noscopy. Thus, my only question is, have you or your surgical col-
league, Dr Harley, considered using mediastinoscopy for those 4
potential EBUS false-negative findings? Again, I think it is crucial,
and we do that for all our patients. If we have an EBUS-negative
finding, the patient undergoes mediastinoscopy; however, if it is
positive, wewill not have the patient undergo SRS because it might
be inappropriate therapy. Has that been done yet?
Dr Krimsky. I think had we not done the additional interroga-
tion and studied our mediastinal data comparing 1 test, at least at
our institution, with the other, than I think yes, but, however, the
data seem to be consistent. I think, again, it does bring up the
idea of stageN1 disease, because, as best I can tell, if you are beam-
ing something over here and you have a hilar node down here, it is 2
separate things altogether. I hope that answers the question.
Dr Hiran C. Fernando (Boston, Mass). Congratulations on the
presentation. I think this is really important to be doing in patients
who are going to be treated with nonoperative therapies.
In the abstract, you say that there is a 16% false-negative rate,
but you are talking only about CT staging, yet you presented
data on PET. Thus, if you combine the CT and PET information,
what is your true false-negative rate, and how much of that
false-negative rate is N1 disease and how much of that false-neg-
ative rate is N2 disease?
Dr Sarwate.With the PET scan, we had a false-negative rate of
10% and a false-negative rate of about 16% with the CT scan.ardiovascular Surgery c Volume 144, Number 1 85
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Dr Fernando. So, if you combine the CTand the PET informa-
tion together, what is your true false-negative rate, using the best
clinical staging that you would have up to this point?
Dr Sarwate. That would be around 8%.
DrMeyers. I am going to turn it around a little bit. Dr Fernando,
you are the primary investigator for the very important American
College of Surgeons Oncology Group/Radiation Therapy Oncology
Group trial that is openingvery soon, randomizingbetweenSBRT, as
discussed here, and sublobar resection. What sort of mediastinal
evaluation are you requiring for that study that is opening soon?
Dr Fernando. Doing something like this would be perfect for
the study, but I do not think we could really mandate that in all
the sites, because 1 of the problems is patient accrual, and this
study is going to be a 422-patient study, and to have all sites doing
EBUS for every patient would not be practical. It would be perfect
if we could do this.
Dr Meyers. So CT and PET?
Dr Fernando.We are doing CTand PETand then invasive me-
diastinal staging or EBUS or endoscopic ultrasonography for those
lymph nodes that look suspicious by CT and/or PET.
Dr Paul Van Schil (Edegem, Belgium). Thank you for indeed
for stressing a very important point, because radiation oncologists
do not always pay enough attention to the lymph nodes.
I have 2 questions. You discovered N1 disease in some patients.
Would you consider adding chemotherapy to the radiotherapy for
those patients?
Dr Krimsky.Granted, there is a lot of controversy with that sit-
uation right now. I think we have left that to the discretion of the
medical oncologists, but it is certainly an interesting consideration,
especially in this patient population.
Dr Van Schil. Second, how far should you gowith this staging?
Current guidelines state that when you have negative EBUS find-
ings and a suspicious lymph node on CTor PET, you should go for
an invasive staging procedure. Would you consider mediastino-
scopy in some patients to include the mediastinum in the radiation
field in case you find N2 disease?
Dr Krimsky. I think that brings us back to Dr Krasna’s ques-
tion. We had been doing that, but we then looked at the data gen-
erated from mediastinoscopy, as well as the data generated from
EBUS, and, given the correlation, it seemed to be reasonable to
proceed at that point with just the EBUS findings alone. In addi-
tion, again, N1 disease is not picked up, so you are stuck with ei-
ther thoracoscopy or something else if you are looking at the hilar.
Dr Joseph B. Shrager (Stanford, Calif). I would like to make
a brief comment.
It is interesting that the radiation oncologists have moved in
general before SBRT to using just PET to decide what their fields
are going to be, and in a number of places, that is all they do. So we
have to kind of bring them back and remind them that they should
not be doing that with SBRT and that they are using an absolutely86 The Journal of Thoracic and Cardiovascular Surgeuseless therapy if they have not evaluated themediastinal nodes for
patients who are at any risk of having mediastinal nodal disease.
DrMeyers.You can say that, but their failure rate is not 16%. It
is much lower than that in patients they have selected. So, there
might be some paradox going on with the kinder immune response
after SBRT, but they do not fail at that high rate.
Dr Shrager. It is possible.
Dr JoachimSchirren (Wiesbaden, Germany).Excellent results.
You showed us that the staging in the mediastinum, with all the
technical aspects, is never correct; therefore, the question: What
will you do with the high-risk patient who receives SBRT? My
question is, could you imagine that video-assisted mediastino-
scopic lymphadenectomy or transcervical extended mediastinal
lymphadenectomy could be the right treatment of this patient,
that we have a very good resection of the lymph nodes without
compromising the patient, and then this procedure will be better
for this high-risk patient?
Dr Krimsky. In other words, surgery versus—perhaps I did not
understand the question.
DrSchirren. I think the nodes, they are never cleared completely;
therefore, perform video-assisted mediastinoscopic lymphadenec-
tomy or transcervical extended mediastinal lymphadenectomy and
resect the nodes. This is not compromising for the patient. You
have thenodes resected.Youhave avery good staging, better staging,
just as with EBUS. I like EBUS, but not in such cases, and then you
can send this patient for SBRT.
Dr Krimsky. Perhaps, yes.
Dr Shrager. Are you familiar with video-assisted mediastino-
scopic lymphadenectomy and transcervical extended mediastinal
lymphadenectomy, these methods of minimally invasively resect-
ing all the nodes?
Dr Krimsky. Yes.
Dr Kazuhiro Yasufuku (Toronto, Ontario, Canada). Thank
you very much for the excellent presentation.
I have 1 comment and 1 question. I think the point that we can
get N1 nodes is a big value of EBUS, because with SBRT, we can
assess the mediastinum with mediastinoscopy, but we cannot get
the N1 nodes with mediastinoscopy. From the results of your ret-
rospective study, what would your recommendations be for per-
forming EBUS for patients who are considered for SBRT?
Would you do EBUS for all patients, regardless of the CT or
PET findings, or would you just include patients who have positive
CT or PET findings?
Dr Krimsky. I think that is a great question, but I think actually
our results bear out what is in fact generally accepted in terms of the
size/staging in terms of the lesion itself. We are finding a number of
these are in lesions that are 2 cmorgreater, but those 2 cmor less,we
find a lot fewer. So, I think right now it seems that that guideline and
that suggestion still seems to hold a lot of value. Again, it is another
procedure. I think what Drs Whyte and Krasna also brought up is,
you know, do you need FMs, and this just happened to be something
that was concomitant for us. I hope that answers the question.ry c July 2012
